Cabozantinib is an orally administered tyrosine kinase inhibitor designed to interfere with signaling pathways that tumors use to grow, invade surrounding tissues and recruit blood vessels. Its molecular targets include vascular endothelial growth factor receptors, particularly VEGFR2, as well as MET and AXL, proteins associated with angiogenesis, metastatic behavior and resistance to therapy. By blocking these kinases, cabozantinib can disrupt both the cancer cell and the tumor microenvironment. The drug has become an established treatment in several oncology settings, including renal cell carcinoma and selected thyroid and liver cancers, making it a valuable starting point for further medicinal-chemistry innovation.

Zanzalintinib, also known as XL092 during its development, belongs to the same broad family of kinase inhibitors but is not simply cabozantinib under a new name. It is an investigational compound built around the idea that carefully selected structural adjustments can alter a molecule’s biological profile without abandoning the pharmacological logic that made its predecessor effective. The central scientific question is not whether the new molecule looks radically different, but whether small changes can tune properties such as target selectivity, tissue distribution, metabolic stability, dosing behavior and tolerability.

That distinction is crucial in kinase drug design. A compound can bind several enzymes with related structures, but the strength and duration of those interactions may vary significantly after even modest chemical editing. Changes to substituents, hydrogen-bonding groups, ring systems or the molecule’s three-dimensional shape can influence how tightly it fits into a kinase’s ATP-binding pocket. They can also affect how rapidly the liver metabolizes the compound, how it crosses cell membranes and how long therapeutically useful concentrations remain in the bloodstream. In oncology, where treatment may continue for months or years, these pharmacological details can determine whether a promising mechanism becomes a practical medicine.

The cabozantinib-to-zanzalintinib story therefore illustrates a form of molecular optimization that is more subtle than the discovery of an entirely new chemical class. Instead of starting from an empty research program, scientists can use an existing drug as a map of validated biology. The original medicine identifies pathways worth targeting, reveals clinically relevant exposure levels and provides information about toxicities and resistance. Researchers can then modify the structure to seek a different balance between potency and safety. The result may retain the parent drug’s therapeutic rationale while opening opportunities for new combinations, disease settings or treatment schedules.

The authors describe this approach as a new frontier in product hopping because the modifications can be chemically obvious in retrospect yet strategically important in practice. “Obvious” does not mean effortless. Medicinal chemistry often advances through hundreds or thousands of analogues, each differing by a small change, before one achieves the desired combination of activity, selectivity and drug-like behavior. A fluorine atom, an altered linker or a replacement ring can change a molecule’s electronic properties, shape and interaction with proteins. The challenge is to identify which apparently minor edits produce a meaningful clinical advantage rather than merely a cosmetic variation.

The commercial implications are substantial. A follow-on molecule based on an established drug can benefit from years of prior biological knowledge, manufacturing experience and clinical precedent. At the same time, it may create new intellectual-property positions and support a fresh development program as the original product approaches the limits of its patent life or market opportunity. For companies, this can reduce some of the uncertainty associated with discovering a medicine from scratch. For patients, the strategy could produce compounds that are easier to tolerate, more convenient to administer or better suited to combination therapy. But it also raises a longstanding question: when does a genuine therapeutic improvement become little more than a commercial extension of an existing product?

That question is especially important for targeted cancer medicines, because their clinical value depends on more than laboratory potency. A new kinase inhibitor must demonstrate that its altered profile translates into improved outcomes, manageable adverse effects or meaningful activity in patients whose tumors have stopped responding to earlier treatments. If zanzalintinib can offer a distinct balance of VEGFR, MET and TAM-family kinase activity, for example, its potential may lie not only in replacing cabozantinib but also in being paired with immunotherapies or other targeted agents. Such combinations require careful attention to overlapping toxicities, pharmacokinetic interactions and the biological consequences of simultaneously suppressing several signaling networks.

The case also highlights how modern drug development increasingly blurs the boundaries between innovation and refinement. Breakthroughs do not always arrive as entirely new molecular architectures. Sometimes they emerge from a disciplined re-examination of a known scaffold, guided by structural biology, computational modeling, pharmacology and clinical experience. The authors’ analysis suggests that the next generation of pharmaceutical competition may be shaped by these “obvious” modifications: changes that appear small on the page but can redirect a drug’s behavior inside the body. Whether that strategy delivers genuine progress will ultimately depend on evidence from clinical trials, not on chemical novelty alone.

Subject of Research: Product hopping and medicinal-chemistry optimization in the development of zanzalintinib from cabozantinib.

Article Title: From cabozantinib to zanzalintinib: obvious chemical modifications as a new frontier in product hopping.

Article References: Strohbehn, G.W., Tu, S.S., Wang, X. et al. From cabozantinib to zanzalintinib: obvious chemical modifications as a new frontier in product hopping. Nat Biotechnol 44, 1274–1279 (2026). https://doi.org/10.1038/s41587-026-03242-w

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03242-w

Keywords: Cabozantinib, zanzalintinib, product hopping, medicinal chemistry, tyrosine kinase inhibitors, cancer therapeutics, drug development, pharmaceutical innovation.

Breast cancer remains a leading cause of cancer morbidity and mortality among women worldwide. Despite advances in detection and therapy, resistance to single-agent treatments and adverse side effects continue to challenge clinicians and researchers alike. Combination therapy has emerged as a strategic solution, offering a multifaceted attack on tumor cells while potentially reducing drug dosages and limiting resistance development. This study specifically highlights the novel pairing of hydralazine and ATRA as a promising example of such an approach.

Hydralazine, traditionally prescribed for hypertension, has gained attention in oncology due to its epigenetic effects, specifically its ability to reverse DNA methylation patterns in cancer cells. These epigenetic modifications often silence tumor suppressor genes, promoting unchecked cell growth. By demethylating DNA, hydralazine can reactivate these critical genes, disrupting malignant processes. However, paradoxically, hydralazine alone was observed in this study to stimulate breast cancer cell growth, underscoring the complexity of its biological effects.

All-trans retinoic acid, on the other hand, is a metabolite of vitamin A that regulates gene expression by binding to nuclear retinoic acid receptors. ATRA plays vital roles in cell differentiation, proliferation, and apoptosis, making it an attractive candidate in cancer therapy. Deficiency in vitamin A and its derivatives has been implicated in the progression of varied disease states, including malignancies. In this investigation, ATRA alone reduced viability in both cancerous and normal cells, reflecting its potent biological influence but also raising concerns about toxicity.

The crux of this research lies in examining the combined effects of hydralazine and ATRA on breast cancer cells versus normal cells. Using robust bioinformatics analyses, the authors identified key pathways such as Hypoxia-Inducible Factor 1 (HIF-1), Vascular Endothelial Growth Factor (VEGF), and WNT signaling as critical mediators of breast cancer progression. These pathways regulate crucial genes including CCND1, VEGFA, VEGFA2, HIF1A, and the antisense transcript HIF1A-AS, which collectively influence tumor growth, angiogenesis, and adaptation to hypoxic tumor microenvironments.

Experimentally, the study employed two cell lines: MDA-MB-231, representing aggressive triple-negative breast cancer cells, and MCF10, a non-tumorigenic mammary epithelial cell line. Employing the MTT assay, researchers calculated the half-maximal inhibitory concentrations (IC50) of hydralazine and ATRA, both alone and in combination. While hydralazine alone unexpectedly promoted MDA-MB-231 proliferation, ATRA reduced survival rates in both cell types, although with significant toxicity to normal cells.

Strikingly, the combination of hydralazine and ATRA produced a synergistic effect, significantly suppressing breast cancer cell viability while preserving the survival of normal mammary cells. This differential cytotoxicity highlights the therapeutic window that the drug pairing may exploit, enhancing cancer cell killing while minimizing collateral damage to healthy tissues—a critical consideration for clinical applications.

Further mechanistic insights were obtained through wound healing assays, revealing that the combination impairs the migratory capacity of cancer cells, a hallmark of metastatic potential. Real-time PCR analyses substantiated these phenotypic observations, demonstrating downregulation in the expression of oncogenes and hypoxia-associated genes, effectively targeting cancer cells’ ability to adapt and survive under low-oxygen conditions commonly seen in solid tumors.

The implications of interfering with hypoxia pathways hold particular promise. Hypoxic environments within tumors are notorious for fostering aggressive cancer phenotypes, contributing to resistance against conventional therapies and fueling vascular proliferation through VEGF signaling. By disrupting HIF-1 and VEGF activity, the hydralazine/ATRA regimen potentially starves the tumor of critical survival cues, amplifying therapeutic efficacy.

Importantly, the study addresses a significant challenge in cancer treatment: medicinal toxicity. ATRA’s efficacy is often counterbalanced by its adverse effects on normal cells, but its combination with hydralazine appears to mitigate this issue, offering a more targeted and less harmful approach to breast cancer management. This finding paves the way for future in vivo studies and clinical trials to evaluate the treatment’s safety and effectiveness on a systemic level.

Moreover, this research underscores the value of integrating computational bioinformatics with empirical laboratory work to unravel complex disease pathways and drug interactions. The bioinformatic prioritization of candidate gene targets, combined with rigorous experimental validation, exemplifies a powerful paradigm in the rational design of novel cancer therapeutics.

While these promising results lay strong groundwork, the authors emphasize that clinical trial validation remains necessary. The current investigation was preclinical, focusing on established cell lines and molecular assays. Future studies aimed at exploring pharmacokinetics, dosing strategies, and long-term outcomes in animal models and patients will be crucial for translating these findings to bedside applications.

This innovative study contributes to the expanding field of epigenetic therapies in oncology. By illuminating how a repurposed antihypertensive drug can synergize with a vitamin A derivative to selectively hinder breast cancer cell proliferation and stress adaptation, it opens exciting prospects for more effective, personalized cancer treatments.

In conclusion, the hydralazine and all-trans retinoic acid combination emerges as a compelling candidate for targeted breast cancer therapy. Its ability to differentially affect malignant and normal cells while impacting key biological pathways central to tumor survival represents a beacon of hope in the ongoing battle against breast cancer—potentially ushering in treatments that are as strategically nuanced as the disease itself.

Subject of Research: Combination of hydralazine and all-trans retinoic acid targeting breast cancer cells.

Article Title: Combination of hydralazine and all-trans retinoic acid targeting breast cancer cells.

Article References:
Yahyapour, A., Askari, N. & Yaghoobi, M.M. Combination of hydralazine and all-trans retinoic acid targeting breast cancer cells. BMC Cancer 25, 1427 (2025). https://doi.org/10.1186/s12885-025-14477-2

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14477-2

Colon cancer remains among the most lethal malignancies worldwide, largely due to its complex pathophysiology and resistance to conventional treatments. The newly identified protein, ENTR1, also recognized as Serologically Defined Colon Cancer Antigen 3 (SDCCAG3), has caught the attention of researchers due to its integral role in protein trafficking within the cell. ENTR1’s function in endosomal transport was known, but its implication in cancer metabolism had not been previously explored with such depth. This study bridges that critical knowledge gap, providing compelling evidence that ENTR1 modulates tumor growth by orchestrating glycolytic pathways.

Energy metabolism reprogramming, especially enhanced glycolysis or the “Warburg effect,” is a hallmark of cancer cells, enabling rapid proliferation even in oxygen-rich environments. The research team embarked on a comprehensive investigation, analyzing ENTR1 expression patterns across normal and tumor tissues using extensive clinical datasets. The data revealed consistent upregulation of ENTR1 in a variety of tumors, including colon cancer, hinting at its possible oncogenic role. By leveraging Mendelian randomization, a sophisticated genetic epidemiology method, they further unraveled a causal relationship implicating ENTR1 as a driver of colon cancer susceptibility.

Beyond observational data, the study harnessed the power of machine learning algorithms combined with metabolite-based Mendelian randomization to dissect the metabolic consequences of ENTR1 dysregulation. These high-throughput computational techniques illuminated a nexus between heightened ENTR1 activity and augmented glycolytic flux in cancer cells. This metabolic reprogramming fuels the aggressive growth patterns observed in colon tumors, pinpointing ENTR1 as a critical molecular switch that toggles energy pathways in favor of malignancy.

Validating these computational findings, in vitro experiments utilizing the HCT-116 colon cancer cell line demonstrated that knocking out ENTR1 expression markedly diminishes cellular proliferation. This perturbation also led to a significant reduction in the expression of key glycolytic enzymes, underscoring the protein’s direct influence on metabolic machinery. Through this functional validation, the study not only confirms ENTR1’s oncogenic role but also highlights its potential as a strategic target to disrupt cancer metabolism therapeutically.

The research design, marked by an integrative approach spanning clinical data mining, genetic epidemiology, machine learning, and bench experiments, exemplifies the cutting-edge methodology necessary to tackle complex cancer biology questions today. It underscores the utility of Mendelian randomization not only to establish causality but to identify metabolic pathways that could be exploited for intervention. ENTR1’s role as a metabolic regulator therefore represents a paradigm shift in understanding how intracellular trafficking proteins may influence tumor energetics and growth.

Intriguingly, the study’s findings resonate with the growing body of literature linking aberrant intracellular trafficking and endosomal dynamics to cancer progression. ENTR1, situated at this intersection, may coordinate not just metabolic enzyme expression but also the subcellular localization and function of signaling molecules pivotal for tumor survival. Such multifaceted roles emphasize the necessity of exploring ENTR1 within broader cellular contexts, which may unveil additional vulnerabilities in cancer cells.

Translational implications of this discovery are profound. By targeting ENTR1, researchers envision novel therapeutic strategies that could selectively impair cancer cell metabolism without affecting normal cells. Given the heightened glycolytic dependencies of tumors, inhibiting ENTR1 might starve cancer cells of their primary energy source, thereby halting growth and possibly sensitizing tumors to existing treatments. The prospect of targeting a regulator upstream of metabolic enzymes adds a new dimension to cancer metabolic therapies.

Moreover, the study sheds light on the prognostic potential of ENTR1 expression levels. Elevated ENTR1 could serve as a biomarker to identify patients with more aggressive or treatment-resistant colon cancer phenotypes. This would enable clinicians to tailor therapies more effectively and monitor disease progression with greater precision. Integrating ENTR1 assessment into diagnostic workflows could refine patient stratification and therapeutic decision-making.

Despite the exciting revelations, the authors acknowledge the necessity for further research to delineate the exact molecular mechanisms through which ENTR1 controls glycolytic enzyme expression. Investigating its interactions with transcriptional regulators or signaling pathways central to metabolism may provide deeper insights. Animal model studies are also warranted to assess the systemic effects and therapeutic potential of ENTR1 modulation in vivo.

In addition to colon cancer, the upregulation of ENTR1 observed across multiple tumor types hints at a broader oncogenic role. Future expansive studies across diverse cancers could establish whether ENTR1-driven metabolic rewiring is a common thread among malignancies, suggesting wide applicability of ENTR1-targeted treatments. Cross-cancer comparisons might also reveal tumor-type-specific differences in ENTR1 function and regulatory networks.

This research exemplifies the power of integrative, multidisciplinary approaches in unraveling cancer biology’s intricacies. By combining computational genetics, metabolomics, and molecular biology, the team has crafted a compelling narrative of how a trafficking regulator affects the metabolic fate of cancer cells, reinforcing the idea that metabolism and intracellular transport are intertwined drivers of oncogenesis.

As cancer research continues to navigate the complex interplay between genetics, metabolism, and cellular dynamics, proteins like ENTR1 offer promising targets that transcend traditional therapeutic categories. The potential to manipulate energy supply at the molecular transport level could revolutionize treatment paradigms, shifting the focus from symptom management to metabolic disruption.

Importantly, these findings come at a crucial time when the oncology field is intensely exploring metabolism-based therapies. The identification of ENTR1’s role aligns with efforts to find novel vulnerabilities in cancer’s metabolic network, reinforcing the critical importance of studying non-canonical regulators that orchestrate tumor energetics beyond classic metabolic enzymes.

Looking ahead, partnerships between academic researchers, pharmaceutical developers, and clinical practitioners will be essential to translate these findings into effective treatments. Drug development efforts targeting ENTR1 could pave the way for a new class of therapeutics that impair tumor metabolism with high specificity and minimal toxicity.

In summary, this study offers a transformative insight into how ENTR1 promotes colon cancer progression by modulating glycolysis and energy metabolism. By revealing ENTR1 as a crucial metabolic regulator and oncogenic driver, the research paves the way for innovative therapeutic strategies that exploit metabolic dependencies in cancer. It highlights the untapped potential of intracellular trafficking proteins as key players in cancer biology and treatment, marking a significant milestone in the ongoing battle against colon cancer.

Subject of Research: The role of ENTR1 in colon cancer progression through regulation of energy metabolism and glycolysis.

Article Title: ENTR1 affects the progression of colon cancer by regulating energy metabolism under the influence of glycolysis.

Article References:
Ma, A., Zhai, C., He, Q. et al. ENTR1 affects the progression of colon cancer by regulating energy metabolism under the influence of glycolysis. BMC Cancer 25, 992 (2025). https://doi.org/10.1186/s12885-025-14412-5

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14412-5

Navtemadlin is primarily recognized as an MDM2 inhibitor, which enhances the activity of p53, a crucial protein in the cellular response to DNA damage. The p53 protein plays a vital role in regulating cell growth and apoptosis, a process where damaged cells are programmed to die. By increasing p53 activity, navtemadlin has the potential to target glioblastoma cells more effectively, particularly those that possess an intact, non-mutant p53. This selectivity may offer a promising avenue for improving patient outcomes in a disease notorious for its resistance to existing therapies.

In the clinical trial, participants were administered navtemadlin followed by surgical intervention to excise tumor tissue. This unique "window of opportunity" approach allowed researchers to monitor how well navtemadlin infiltrated the tumor and to examine its impact on the cancer cells directly. The findings indicated that navtemadlin successfully penetrated the tumors and activated the p53 pathway, which is critical in the effort to induce cancer cell death. However, a concerning observation was that despite these promising results, patients eventually experienced tumor relapse, highlighting the persistent challenges in effectively combating glioblastoma.

To further investigate the mechanisms behind this relapse, researchers utilized tissue samples taken from patients who experienced tumor recurrence. These samples were instrumental in creating patient-derived tumor models, providing a robust platform to test various therapeutic strategies. By exploring different dosing regimens and combinations, the scientists discovered that integrating navtemadlin with conventional chemotherapy agents, such as temozolomide, significantly enhanced cancer cell lethality. This combination therapy could represent a transformative step in the fight against glioblastoma, addressing the pressing issue of drug resistance.

The significance of these findings cannot be understated. Glioblastoma is currently treated with a multi-faceted approach, including surgery, radiation, and chemotherapy. Despite this aggressive regimen, survival rates remain discouragingly low, often due to the tumor’s ability to evade treatment and reestablish itself. This study emphasizes the importance of innovative trial designs that facilitate direct tumor sampling during treatment, offering deeper insights into the cellular responses triggered by new therapeutics.

Additionally, the trial underscores the potential of combination therapies to maximize the efficacy of navtemadlin. By utilizing both novel and traditional agents, investigators may not only improve treatment outcomes but also prolong survival and enhance the quality of life for patients battling glioblastoma. The combination strategy aims to overwhelm the cancer’s defenses, reducing its adaptability and resistance to treatment.

As researchers and clinicians continue to unravel the complex biology of glioblastomas, studies like this one pave the way for more personalized and effective treatment protocols. Understanding the nuances of tumor biology and the interactions between different therapeutic agents can lead to more strategic approaches in targeting these formidable cancers. Continuous exploration in this field is essential, as it may eventually yield breakthroughs that can turn the tide against glioblastoma and similar malignancies.

Looking forward, the integration of advanced imaging techniques and molecular profiling in clinical trials could further enhance the understanding of how treatments like navtemadlin function at a cellular level. These methodologies can facilitate the identification of biomarkers that predict treatment response, allowing for tailored interventions that cater to an individual’s unique tumor characteristics. This precision medicine approach holds great promise for addressing the heterogeneity seen in cancer, particularly with conditions as complex as glioblastoma.

The future of glioblastoma treatment may hinge on the insights gained from comprehensive studies combining novel agents with established therapies. The findings from Dana-Farber’s clinical trial represent a significant stride toward developing a potent arsenal in the battle against brain cancer. These efforts reflect a broader commitment within the scientific community to tackle the formidable challenges posed by malignant tumors through innovative research and collaborative endeavors.

The journey towards enhancing glioblastoma treatment is far from over, but with advancements in drug research and a deeper understanding of tumor biology, the hope remains that strategies like the one involving navtemadlin will yield meaningful improvements in patient outcomes. The resilience of glioblastoma cells continues to challenge medical science, yet the proactive efforts of researchers are steadily illuminating the path forward.

As this exciting field of research continues to progress, the health and well-being of glioblastoma patients can hopefully improve through novel therapeutic strategies that harness the power of new drugs like navtemadlin, coupled with traditional chemotherapy regimens. The convergence of innovative science and clinical application could forge a new frontier in the fight against one of the most aggressive cancers known to mankind.

Thus, as the study unfolds, the implications of its findings reverberate through the scientific community, catalyzing new conversations on how to best approach the relentless challenges posed by glioblastoma. The anticipation surrounding the potential of navtemadlin and its combination with existing treatments holds the promise of a brighter future for patients facing this formidable opponent.

In summary, the window of opportunity trial not only highlights the importance of innovative treatment combinations but also reinforces the need for meticulous clinical studies that explore the nuances of drug interactions within the context of complex malignancies like glioblastoma. By continuing to unveil the secrets of cancer biology, researchers may well unlock powerful new treatment paradigms that can redefine standards of care and expand survival horizons for patients.

Subject of Research: Mechanisms of response and resistance to navtemadlin in glioblastoma treatment
Article Title: Window of opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma
News Publication Date: 19-Feb-2025
Web References: Science Translational Medicine
References: Dana-Farber Cancer Institute
Image Credits: N/A
Keywords: glioblastoma, navtemadlin, MDM2 inhibitor, cancer treatment, chemotherapy, p53, clinical trial, resistance, combination therapy, tumor biology, personalized medicine, drug research